UNSPSC 51113300: Alkylating agent carbamates

This classification denotes derivatives of carbamic acid (H2NC(=O)OH) such as N-substituted and O-substituted carbamic acids, that constitute reactive chemicals that introduce into biologically active molecules alkyl radicals and thereby disrupt functioning of the same, substances called alkyl-ating agents, thus the term ALKYLATING AGENT ALKYLATING AGENT CARBAMATES.

UNSPSC 51113300 Alkylating agent carbamates is a Class code that nominally names a family of chemotherapy and immunosuppressant pharmaceuticals; however, the recent state and local procurement activity tagged under this code does not reflect direct procurement of the drugs themselves. Instead, the Texas Health and Human Services Commission issued a Request for Information in April 2026 seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program — a pharmacy benefit and supply-chain management initiative designed to establish direct contracting relationships between state agencies and pharmaceutical manufacturers outside of traditional pharmacy benefit manager and group purchasing organization channels. The RFI solicits vendors' experience with direct contracting for self-insured employers and government health plans, flexibility to negotiate net-pricing models, and capacity to implement outcomes-based agreements. This mismatch between the code's nominal pharmaceutical scope and the actual procurement activity — which targets pharmacy program administration and contracting infrastructure rather than drug acquisition — suggests the code may be misapplied in state and local systems.

The single recent opportunity in the block is the Texas Health and Human Services Commission RFI No. HHS0017013, posted April 3, 2026, with a response deadline of April 3, 2026. No geographic spread beyond Texas is evident from the source, and no other state or local issuing bodies have posted opportunities under this code in the recent-opportunities window. The exploratory nature of the RFI — framed as foundational market intelligence to inform future formal procurement — means no award value, contract duration, or binding timeline is established at this stage. Given the narrow activity and the conceptual distance between the code's pharmaceutical naming and the program-administration focus of the sole recent solicitation, this code shows little actionable procurement signal for vendors selling alkylating agent carbamates or related pharmaceutical products into state and local health systems.